Dan O'Day, Gilead CEO (Kevin Dietsch/UPI/Bloomberg via Getty Images)
February 10, 2021 09:42 AM ESTUpdated 10:47 AM
R&D

Dan O’Day’s $5B deal with Gala­pa­gos im­plodes as PhI­II tri­als col­lapse

John Carroll

Editor & Founder

Gilead’s bat­tle-scarred al­liance with Gala­pa­gos just suf­fered an­oth­er griev­ous wound.

The biotech part­ners re­port­ed Wednes­day morn­ing that they are aban­don­ing their late-stage piv­otal pro­gram for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

A service from the Financial Times